Breast cancer (BC) is prevalent worldwide and is a leading cause of death among women. However, cell-surface glucose-regulated protein 78 (cs-GRP78) is overexpressed in several types of cancer and during ..... see more
Kana Miyahara, Kazutaka Narui, Yukari Uemura, Akimitsu Yamada, Kazuhiro Araki, Fumie Fujisawa, Takahiro Nakayama, Takashi Ishikawa, Naruto Taira, Yuichiro Kikawa, Tomohiko Aihara, Hirofumi Mukai Abstract Background: Combination therapy with cyclin-dependent ..... see more
Discussion: In this multi-institutional prospective cohort study, we evaluate the clinical efficacy and safety of combination therapy with abemaciclib and hormonal therapy for chemotherapy-treated patients with HR HER2- MBC. We also evaluate this combination therapy as maintenance therapy in patients who respond to early-line chemotherapy.
Micro-AbstractA 20-year retrospective review of locoregional recurrences, secondary cancers, and atypical breast neoplasms after autologous tissue reconstruction for cancer of the breast identified an overall recurrence rate of 5.3%. The ..... see more
Conclusion: Our retrospective review found incidence and survival after treatment of breast cancer concordant with reports in the literature. We also identified and analyzed secondary neoplasms, including a unique case of undifferentiated pleomorphic sarcoma and metachronous recurrence of breast carcinoma. A case of recurrence as metaplastic...
1 Department of Biology and Biochemistry, University of Bath, Bath BA2 7 AY, UK. 2 Department of Biostatistics and Epidemiology, Gustave Roussy, Paris-Saclay University, 91190 Gif-sur-Yvette, France. 3 Department of ..... see more
Conclusions: Our study strongly supports the notion that CDK4/6 inhibitors induce tumour immune modulation. N/L ratio and platelet levels decreased due to treatment. Future studies should test whether patients would benefit from immunomodulators in association with CDK4/6 agents in a larger clinical trial. Moreover, the CDK4/6-induced immune...
One quarter of all practicing physicians in the United States and over one third of all US hematologists and oncologists are international medical graduates (IMGs). IMGs are defined as physicians ..... see more
Relevance: One quarter of all practicing physicians in the United States and over one third of all US hematologists and oncologists are international medical graduates (IMGs). IMGs are defined as physicians who have graduated from a medical school outside the United States and Canada, a population that includes US citizens and permanent...
BackgroundUpdated evidence was required to compare the efficacy and safety of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) inhibitors ..... see more
doi: 10.1001/jamaoncol.2022.4175. Online ahead of print. 1 Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain. 2 Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer ..... see more
Conclusions and Relevance: This review suggests that ERBB2-low may be a distinct, clinically relevant breast cancer entity warranting reassessment of traditional diagnostic and therapeutic paradigms. Ongoing clinical trials and further investigations may provide optimized strategies for diagnosing and treating ERBB2-low breast cancer,...
These real-world data complement clinical trial results by examining abemaciclib use among patients treated in routine clinical practice. The sizeable number of patients treated with prior CDK4 & 6i, chemotherapy, ..... see more
Conclusion: These real-world data complement clinical trial results by examining abemaciclib use among patients treated in routine clinical practice. The sizeable number of patients treated with prior CDK4 & 6i, chemotherapy, and/or visceral metastases at abemaciclib initiation suggest that many patients had very advanced disease and/or were in...
Providing evidence that there was no loss of efficacy by administering chemotherapy before surgery enabled investigators to exploit the huge translational research opportunities of the neoadjuvant setting. This in turn ..... see more
PURPOSE Despite the growing recognition of the importance of hypertension in patients with cancer, little is known about whether high blood pressure (BP) among patients with cancer is associated with ..... see more
Conclusion: Medication-naïve stage 1 and 2 hypertension was associated with a greater risk of HF and other CVD events in patients with cancer. Our results suggest the importance of multidisciplinary collaboration (eg, oncologists and cardiologists) to establish the optimal management strategy for hypertension in patients with cancer.
Cyclin-dependent kinases, CDK4 and CDK6, are essential in regulating the cell cycle, which is disrupted in cancers like isocitrate dehydrogenase wild-type glioblastoma (GBM). Currently marketed CDK4/6 inhibitors, including abemaciclib, have ..... see more
Triple-negative breast cancer (TNBC) is a breast cancer (BC) subtype characterized by the lack of the three hallmark receptors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor ..... see more
Published systemic therapy options for metastatic extramammary Paget's disease have largely been anecdotal due to the rarity of this disease, which has precluded the ability to conduct clinical trials. We ..... see more
Relevance: Published systemic therapy options for metastatic extramammary Paget's disease have largely been anecdotal due to the rarity of this disease, which has precluded the ability to conduct clinical trials. We describe the favorable response of a 72-year-old man with extramammary Paget's disease, whose disease has been controlled with the...
The pertuzumab study in the neoadjuvant setting for HER2+ nonmetastatic breast cancer in Australia (PeRSIA-ML39622) is an analysis of safety and effectiveness data from the pertuzumab patient registry. Although the ..... see more
Conclusion/Relevance: Our study is the first to capture real-world data on the use of pertuzumab in the neoadjuvant setting in Australia. The effectiveness and safety data are consistent with those reported in clinical trials of pertuzumab in patients with HER2 breast cancer, with no new safety concerns.
Palbociclib, ribociclib and abemaciclib are selective CDK4/6 inhibitors, approved for HR+, HER2-, advanced or metastatic breast cancer * Various mechanisms of primary ( de novo) or acquired resistance to CDK4/6 ..... see more
Steviol glycosides, the active sweet components of stevia plant, have been recently found to possess a number of therapeutic properties, including some recorded anticancer ones against various cancer cell types ..... see more
Conclusion: The above data clearly demonstrate that steviol glycosides have different effects on breast cancer cells according to their ER status, suggesting that steviol glycosides might be examined for their potential anticancer activity against breast cancer, especially triple negative breast cancer (TNBC).
In recent years, the incidence rate of breast cancer has increased year by year, and it has become a major threat to the health of women globally. Among all breast ..... see more
Despite being a standard treatment option in breast cancer, immune checkpoint inhibitors (ICIs) are only efficacious for a subset of patients. To gain a better understanding of the antitumor immune ..... see more